Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance

This study aimed to evaluate the antimicrobial susceptibility and combination of a beta-blocker, labetalol (LAB) and meropenem (MEM) on Carbapenem-resistant (CR) A. baumannii clinical isolates. A total of 43 CRA. baumannii were isolated of which 37 (86.6 %) and 28 (65 %) exhibited MDR and XDR phenot...

Full description

Bibliographic Details
Published in:DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
Main Authors: Selim, Heba Mohammed Refat M.; Gomaa, Fatma Alzahraa M.; Alshahrani, Mohammad Y.; Kamel, Noha A.; Aboshanab, Khaled M.; Elsayed, Khaled M.
Format: Article
Language:English
Published: ELSEVIER SCIENCE INC 2024
Subjects:
Online Access:https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001337438000001
author Selim
Heba Mohammed Refat M.; Gomaa
Fatma Alzahraa M.; Alshahrani
Mohammad Y.; Kamel
Noha A.; Aboshanab
Khaled M.; Elsayed
Khaled M.
spellingShingle Selim
Heba Mohammed Refat M.; Gomaa
Fatma Alzahraa M.; Alshahrani
Mohammad Y.; Kamel
Noha A.; Aboshanab
Khaled M.; Elsayed
Khaled M.
Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance
Infectious Diseases; Microbiology
author_facet Selim
Heba Mohammed Refat M.; Gomaa
Fatma Alzahraa M.; Alshahrani
Mohammad Y.; Kamel
Noha A.; Aboshanab
Khaled M.; Elsayed
Khaled M.
author_sort Selim
spelling Selim, Heba Mohammed Refat M.; Gomaa, Fatma Alzahraa M.; Alshahrani, Mohammad Y.; Kamel, Noha A.; Aboshanab, Khaled M.; Elsayed, Khaled M.
Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
English
Article
This study aimed to evaluate the antimicrobial susceptibility and combination of a beta-blocker, labetalol (LAB) and meropenem (MEM) on Carbapenem-resistant (CR) A. baumannii clinical isolates. A total of 43 CRA. baumannii were isolated of which 37 (86.6 %) and 28 (65 %) exhibited MDR and XDR phenotypes, respectively. Colistin and doxycycline still retain their activities in 93.1 % and 72.1 % of the isolates, respectively. Combining MEM with LAB at 0.25 mg /mL, decreased MIC values in 91.4 % (32/35) however, at 0.5 mg /mL, it decreased MIC value and restored susceptibility to MEM in 100 % and 91.4 % of the tested isolates, respectively. A novel transferable plasmid pAcbGIM3 harboring aph-3 ', blaoxa-58, blaGIM3 and blaCTX-M3 and eight mobile genetic elements were successfully isolated from a pan-drug resistant (PDR) isolate. In conclusion, LAB-MEM is a promising combination and should be clinically examined. This is the first report of a transmissible plasmid harboring blaGIM3 gene in Egypt.
ELSEVIER SCIENCE INC
0732-8893
1879-0070
2024
110
4
10.1016/j.diagmicrobio.2024.116558
Infectious Diseases; Microbiology

WOS:001337438000001
https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001337438000001
title Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance
title_short Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance
title_full Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance
title_fullStr Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance
title_full_unstemmed Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance
title_sort Colistin, doxycycline and Labetalol-meropenem combination are the most active against XDR-Carbapenem-resistant Acinetobacter baumannii: Role of a novel transferrable plasmid conferring carbapenem resistance
container_title DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
language English
format Article
description This study aimed to evaluate the antimicrobial susceptibility and combination of a beta-blocker, labetalol (LAB) and meropenem (MEM) on Carbapenem-resistant (CR) A. baumannii clinical isolates. A total of 43 CRA. baumannii were isolated of which 37 (86.6 %) and 28 (65 %) exhibited MDR and XDR phenotypes, respectively. Colistin and doxycycline still retain their activities in 93.1 % and 72.1 % of the isolates, respectively. Combining MEM with LAB at 0.25 mg /mL, decreased MIC values in 91.4 % (32/35) however, at 0.5 mg /mL, it decreased MIC value and restored susceptibility to MEM in 100 % and 91.4 % of the tested isolates, respectively. A novel transferable plasmid pAcbGIM3 harboring aph-3 ', blaoxa-58, blaGIM3 and blaCTX-M3 and eight mobile genetic elements were successfully isolated from a pan-drug resistant (PDR) isolate. In conclusion, LAB-MEM is a promising combination and should be clinically examined. This is the first report of a transmissible plasmid harboring blaGIM3 gene in Egypt.
publisher ELSEVIER SCIENCE INC
issn 0732-8893
1879-0070
publishDate 2024
container_volume 110
container_issue 4
doi_str_mv 10.1016/j.diagmicrobio.2024.116558
topic Infectious Diseases; Microbiology
topic_facet Infectious Diseases; Microbiology
accesstype
id WOS:001337438000001
url https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001337438000001
record_format wos
collection Web of Science (WoS)
_version_ 1814778545287725056